Click to Enlarge
Facebook
Twitter
The Financial Times has published a travel special, but its top story is on comments from the chief executive of AstraZeneca, Pascal Soriot. In his first interview since the possible link between the jab and rare blood clots, Mr Soriot defended the vaccine and told the FT it was only slightly less effective against the Indian variant. He also said the new booster jab performed well against variants